Greater Manchester Medicines Management Group

Greater Manchester Clinical Standards Board



<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during October 2017

October 2017

Pathways and Guidelines Development Subgroup (PaGDSG)


The following revised and updated Shared Care Protocols were approved at the October 2017 meeting of GMMMG:

  • Antipsychotics for Bipolar Disorder in children and adolescents
  • Antipsychotics for the treatment of OCD in children and adolescents
  • Antipsychotics for Psychosis and Schizophrenia in children and adolescents
  • SSRIs for the treatment of Anxiety Disorders in children and adolescents
  • SSRIs for the treatment of Depression in children and adolescents
  • SSRIs for the treatment of OCD and Body Dysmorphic Disorder (BDD) in children and adolescents
  • Azathioprine and 6-Mercaptopurine for the treatment of IBD
  • Denosumab for osteoporosis


The following guideline updated guideline was approved at the October 2017 meeting of the GMMMG to include the addition of rupatadine:

Formulary and Managed Entry Subgroup (FMESG)


Please note that an interim position statement for FreeStyle Libre® has been issued by GMMMG. A full recommendation is currently being developed so this position will be updated as soon as possible.

High Cost Drugs Subgroup (HCDSG)


The GMMMG High Cost Drugs Subgroup (HCDSG) met on the 5th October (postponed Sept meeting), there was no August meeting.

The minutes of the July meeting are now available here.

At the Sept meeting the group:

  • Approved the “HCD pathway for psoriasis” which has now been approved by GMMMG
  • Discussed the availability of the BSR register to all biosimilar products, discussions are ongoing via NHSE
  • Agreed that a draft “Free of Charge Medicines Scheme” policy be developed
  • Agreed to recommend actions from the NHSE Commissioning Framework for Biologics be included within the commissioning intentions for next year
  • The group agreed to produce a paper titled the “GM wide optimum management of biologics”, which will incorporate gain share arrangements for dose tapering. This work will link with the work undertaken by the GM rheumatology network
  • The group are working towards a draft data platform to present biosimilar uptake rates across GM
  • The revised GM IBD pathway and the updated Botulinum toxin policy are open for GM wide consultation
  • The Blueteq forms for Macular Drug pathway will be enabled on the system
  • The review of the HCD data challenges has been added to the GMMMG members part of the GMMMG website for information


The Greater Manchester biologics pathway for inflammatory bowel disease [Link removed - consultation closed] has been updated with input from clinical specialists and with the support of Greater Manchester Shared Service. This version has been updated to incorporate NICE TA456: Ustekinumab to treat moderately to severe Crohn’s disease.

This pathway is intended for use in patients with severe Crohn’s disease and moderately to severely active ulcerative colitis, within the Greater Manchester health economy.

We seek the comments of all GM NHS healthcare professionals.

This consultation period is open until 5pm Friday October 27th 2017, comments should be submitted via the Feedback Form [Link removed - consultation closed]

Representatives of the pharmaceutical industry are invited to comment on factual inaccuracies only.



A draft copy of the Greater Manchester botulinum toxin commissioning policy [Link removed - consultation closed] is currently open for GM wide consultation. Comments from GM NHS healthcare professionals are invited.

A supporting information document to compliment the draft Botulinum toxin commissioning policy [Link removed - consultation closed] is also available

<< Back



RSS Feed